130 related articles for article (PubMed ID: 19781726)
1. Antiviral efficacy of EICAR against canine distemper virus (CDV) in vitro.
Dal Pozzo F; Galligioni V; Vaccari F; Gallina L; Battilani M; Scagliarini A
Res Vet Sci; 2010 Apr; 88(2):339-44. PubMed ID: 19781726
[TBL] [Abstract][Full Text] [Related]
2. In vitro efficacy of ribavirin against canine distemper virus.
Elia G; Belloli C; Cirone F; Lucente MS; Caruso M; Martella V; Decaro N; Buonavoglia C; Ormas P
Antiviral Res; 2008 Feb; 77(2):108-13. PubMed ID: 17949825
[TBL] [Abstract][Full Text] [Related]
3. Depletion of GTP pool is not the predominant mechanism by which ribavirin exerts its antiviral effect on Lassa virus.
Ölschläger S; Neyts J; Günther S
Antiviral Res; 2011 Aug; 91(2):89-93. PubMed ID: 21616094
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of viral RNA synthesis in canine distemper virus infection by proanthocyanidin A2.
Gallina L; Dal Pozzo F; Galligioni V; Bombardelli E; Scagliarini A
Antiviral Res; 2011 Dec; 92(3):447-52. PubMed ID: 22020306
[TBL] [Abstract][Full Text] [Related]
5. In-vitro antiviral efficacy of ribavirin and interferon-alpha against canine distemper virus.
Carvalho OV; Saraiva GL; Ferreira CG; Felix DM; Fietto JL; Bressan GC; Almeida MR; Silva Júnior A
Can J Vet Res; 2014 Oct; 78(4):283-9. PubMed ID: 25355997
[TBL] [Abstract][Full Text] [Related]
6. In vitro antiviral efficacy of caffeic acid against canine distemper virus.
Wu ZM; Yu ZJ; Cui ZQ; Peng LY; Li HR; Zhang CL; Shen HQ; Yi PF; Fu BD
Microb Pathog; 2017 Sep; 110():240-244. PubMed ID: 28687324
[TBL] [Abstract][Full Text] [Related]
7. The anti-yellow fever virus activity of ribavirin is independent of error-prone replication.
Leyssen P; De Clercq E; Neyts J
Mol Pharmacol; 2006 Apr; 69(4):1461-7. PubMed ID: 16421290
[TBL] [Abstract][Full Text] [Related]
8. Ribavirin and boceprevir are able to reduce Canine distemper virus growth in vitro.
Lanave G; Cavalli A; Martella V; Fontana T; Losappio R; Tempesta M; Decaro N; Buonavoglia D; Camero M
J Virol Methods; 2017 Oct; 248():207-211. PubMed ID: 28760649
[TBL] [Abstract][Full Text] [Related]
9. The predominant mechanism by which ribavirin exerts its antiviral activity in vitro against flaviviruses and paramyxoviruses is mediated by inhibition of IMP dehydrogenase.
Leyssen P; Balzarini J; De Clercq E; Neyts J
J Virol; 2005 Feb; 79(3):1943-7. PubMed ID: 15650220
[TBL] [Abstract][Full Text] [Related]
10. 1-beta-D-ribofuranosyl-1,2,4-triazole-3-carboxamide (ribavirin) and 5-ethynyl-1-beta-D-ribofuranosylimidazole-4-carboxamide (EICAR) markedly potentiate the inhibitory effect of 2',3'-dideoxyinosine on human immunodeficiency virus in peripheral blood lymphocytes.
Balzarini J; Lee CK; Schols D; De Clercq E
Biochem Biophys Res Commun; 1991 Jul; 178(2):563-9. PubMed ID: 1650194
[TBL] [Abstract][Full Text] [Related]
11. Antiviral efficacy of favipiravir against canine distemper virus infection in vitro.
Xue X; Zhu Y; Yan L; Wong G; Sun P; Zheng X; Xia X
BMC Vet Res; 2019 Sep; 15(1):316. PubMed ID: 31477101
[TBL] [Abstract][Full Text] [Related]
12. Activity of ribavirin against Hantaan virus correlates with production of ribavirin-5'-triphosphate, not with inhibition of IMP dehydrogenase.
Sun Y; Chung DH; Chu YK; Jonsson CB; Parker WB
Antimicrob Agents Chemother; 2007 Jan; 51(1):84-8. PubMed ID: 17060520
[TBL] [Abstract][Full Text] [Related]
13. In vitro inhibition of canine distemper virus by flavonoids and phenolic acids: implications of structural differences for antiviral design.
Carvalho OV; Botelho CV; Ferreira CG; Ferreira HC; Santos MR; Diaz MA; Oliveira TT; Soares-Martins JA; Almeida MR; Silva A
Res Vet Sci; 2013 Oct; 95(2):717-24. PubMed ID: 23664014
[TBL] [Abstract][Full Text] [Related]
14. Antiviral activities of ribavirin, 5-ethynyl-1-beta-D-ribofuranosylimidazole-4-carboxamide, and 6'-(R)-6'-C-methylneplanocin A against several ortho- and paramyxoviruses.
Shigeta S; Mori S; Baba M; Ito M; Honzumi K; Nakamura K; Oshitani H; Numazaki Y; Matsuda A; Obara T
Antimicrob Agents Chemother; 1992 Feb; 36(2):435-9. PubMed ID: 1605607
[TBL] [Abstract][Full Text] [Related]
15. Effective primary isolation of wild-type canine distemper virus in MDCK, MV1 Lu and Vero cells without nucleotide sequence changes within the entire haemagglutinin protein gene and in subgenomic sections of the fusion and phospho protein genes.
Lednicky JA; Meehan TP; Kinsel MJ; Dubach J; Hungerford LL; Sarich NA; Witecki KE; Braid MD; Pedrak C; Houde CM
J Virol Methods; 2004 Jun; 118(2):147-57. PubMed ID: 15081610
[TBL] [Abstract][Full Text] [Related]
16. Antiviral effect of ribavirin on Junin virus replication in vitro.
Rodríguez M; McCormick JB; Weissenbacher MC
Rev Argent Microbiol; 1986; 18(2):69-74. PubMed ID: 2825242
[TBL] [Abstract][Full Text] [Related]
17. Mechanism-based design of inosine 5-monophosphate dehydrogenase inhibitors: synthesis and biological activities of 5-ethynyl-1-beta-D-ribofuranosylimidazole-4-carboxamide (EICAR) and its derivatives.
Minakawa N; Matsuda A
Curr Med Chem; 1999 Jul; 6(7):615-28. PubMed ID: 10390604
[TBL] [Abstract][Full Text] [Related]
18. The anti-canine distemper virus activities of ex vivo-expanded canine natural killer cells.
Park JY; Shin DJ; Lee SH; Lee JJ; Suh GH; Cho D; Kim SK
Vet Microbiol; 2015 Apr; 176(3-4):239-49. PubMed ID: 25680810
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of Junin virus RNA synthesis by an antiviral acridone derivative.
Sepúlveda CS; García CC; Fascio ML; D'Accorso NB; Docampo Palacios ML; Pellón RF; Damonte EB
Antiviral Res; 2012 Jan; 93(1):16-22. PubMed ID: 22027649
[TBL] [Abstract][Full Text] [Related]
20. Mechanism of reduction of virus release and cell-cell fusion in persistent canine distemper virus infection.
Meertens N; Stoffel MH; Cherpillod P; Wittek R; Vandevelde M; Zurbriggen A
Acta Neuropathol; 2003 Oct; 106(4):303-10. PubMed ID: 12827396
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
